Latest News Opternative Secures $9 Million in Series A3 Round of Funding By Staff Friday, November 9, 2018 12:24 AM CHICAGO—The eye health care technology company Opternative announced Thursday that is has secured $9 million in an “A3” round of funding, bringing to $18.5 million the total investment the company has raised to date, a spokeswoman told VMAIL. Trust Ventures and Pritzker Group Venture Capital led the funding round, with an additional investment from existing investor Jump Capital, according to the announcement. Opternative said it will use the funding to double its engineering, product, sales and marketing teams. The funding also will be used “to grow awareness and adoption of [the company’s] online vision test with consumers, employers and eyecare providers,” the announcement noted. “With this latest round of funding, Opternative is now poised to significantly grow its position as a pioneer in the eye health care technology space,” Trust Ventures founder and general partner Salen Churi said in the announcement. “This investment solidifies Opternative as one of Chicago’s most promising and innovative companies.”Peter Liu, vice president of Pritzker Group Venture Capital, said he believes Opternative is at “the forefront of eye health care technology by expanding its national and global reach of its leading digital vision test.” He added, “I am thrilled to be on the board of such a cutting-edge company and look forward to working closing with Opternative on its long-term growth plans.”Opternative chief executive officer Brent Rasmussen said the new round of funding represents “only the beginning of great things to come” for the technology firm. “We’ve had great success in partnering with eyewear retailers and eyecare providers, and this meaningful investment is a great affirmation of the tremendous traction we’ve achieved and will enable us to aggressively focus on continued international growth and furthering our partnerships with everyone in the industry,” he added.Opternative, founded in 2012, has issued “hundreds of thousands of prescriptions with a 99.6 percent satisfaction rate,” and more than 1 million consumers have utilized its eye test, the company said.